




# Use of kinase inhibitors against schistosomes to improve and broaden praziquantel efficacy

Sujeevi S. K. Nawaratna<sup>1,2</sup>, Donald P. McManus<sup>1</sup> , Robin B. Gasser<sup>3</sup>, Paul J. Brindley<sup>4</sup>, Glen M. Boyle<sup>1</sup>, Vanessa Rivera<sup>1,5</sup>, Shiwanthi L. Ranasinghe<sup>1</sup>, Malcolm K. Jones<sup>6</sup> , Hong You<sup>1,\*</sup>  and Geoffrey N. Gobert<sup>1,7,\*</sup>

## Research Article

\*These authors contributed equally.

**Cite this article:** Nawaratna SSK *et al.* (2020). Use of kinase inhibitors against schistosomes to improve and broaden praziquantel efficacy. *Parasitology* **147**, 1488–1498. <https://doi.org/10.1017/S0031182020001250>

Received: 17 May 2020  
Revised: 7 July 2020  
Accepted: 8 July 2020  
First published online: 3 August 2020

### Key words:

1Naphthyl PP1; adjunct therapy; CaMK; CaMKII; kinase inhibitors; praziquantel; *Schistosoma mansoni*; schistosomula; Staurosporine; STSP

### Author for correspondence:

Geoffrey N. Gobert,  
E-mail: [G.Gobert@qub.ac.uk](mailto:G.Gobert@qub.ac.uk);  
Hong You,  
E-mail: [Hong.You@qimrberghofer.edu.au](mailto:Hong.You@qimrberghofer.edu.au)

<sup>1</sup>QIMR Berghofer Medical Research Institute, Herston, Australia; <sup>2</sup>School of Medicine, Griffith University, Gold Coast, Australia; <sup>3</sup>Department of Veterinary Biosciences, Melbourne Veterinary School, The University of Melbourne, Parkville, Australia; <sup>4</sup>School of Medicine and Health Sciences, George Washington University, Washington DC, USA; <sup>5</sup>School of Medicine, Deakin University, Geelong, Australia; <sup>6</sup>School of Veterinary Science, The University of Queensland, Gatton, Australia and <sup>7</sup>School of Biological Sciences, Queen's University Belfast, Belfast, UK

### Abstract

Praziquantel (PZQ) is the drug of choice for schistosomiasis. The potential drug resistance necessitates the search for adjunct or alternative therapies to PZQ. Previous functional genomics has shown that RNAi inhibition of Ca<sup>2+</sup>/calmodulin-dependent protein kinase II (CaMKII) gene in *Schistosoma* adult worms significantly improved the effectiveness of PZQ. Here we tested the *in vitro* efficacy of 15 selective and non-selective CaMK inhibitors against *Schistosoma mansoni* and showed that PZQ efficacy was improved against refractory juvenile parasites when combined with these CaMK inhibitors. By measuring CaMK activity and the mobility of adult *S. mansoni*, we identified two non-selective CaMK inhibitors, Staurosporine (STSP) and 1Naphthyl PP1 (1NAPP1), as promising candidates for further study. The impact of STSP and 1NAPP1 was investigated in mice infected with *S. mansoni* in the presence or absence of a sub-lethal dose of PZQ against 2- and 7-day-old schistosomula and adults. Treatment with STSP/PZQ induced a significant (47–68%) liver egg burden reduction compared with mice treated with PZQ alone. The findings indicate that the combination of STSP and PZQ dosages significantly improved anti-schistosomal activity compared to PZQ alone, demonstrating the potential of selective and non-selective CaMK/kinase inhibitors as a combination therapy with PZQ in treating schistosomiasis.

## Introduction

Schistosomiasis is a major neglected tropical disease impacting the lives of over 250 million people in 78 countries and 779 million are at risk of infection (McManus *et al.*, 2018). The treatment of choice is praziquantel (PZQ), a drug discovered in the 1970s (Andrews *et al.*, 1983; Chai, 2013). However, a major limitation of PZQ is its lack of efficacy against the immature, migrating stages of the parasite (Xiao *et al.*, 2010, 2018). In addition, reliance on this single compound to treat all *Schistosoma* species is a continuing concern, especially as increases in the use of PZQ in current mass drug administration (MDA) control programmes may result in the development of resistance to the drug (Hotez and Fenwick, 2009; Lo *et al.*, 2017). Therefore, research is required to increase the longevity or efficacy of PZQ.

Although the exact mechanism of action of PZQ remains unclear, its action on calcium homeostasis of mature *Schistosoma* parasites is apparent (Day *et al.*, 1992; Doenhoff *et al.*, 2008; Xiao *et al.*, 2018). The contraction and paralysis observed in PZQ-treated schistosomes are explained by membrane depolarization and the influx of extracellular calcium into the worms, which causes vacuolation and disintegration of the parasite surface (Doenhoff *et al.*, 2008; Xiao *et al.*, 2018). Although the mode of action of PZQ is thought to be multi-faceted (Pica-Mattocchia *et al.*, 2009), a massive influx of calcium ions into the cells possibly *via* the pore-forming  $\alpha 1$  subunit of a calcium channel is a major feature of PZQ sensitivity (Greenberg, 2005).

Previously, we reported the significant upregulation of genes related to calcium signalling pathways and possible drug resistance in schistosome adults following *in vivo* exposure to PZQ in mouse models of schistosomiasis (You *et al.*, 2013). Ca<sup>2+</sup>/calmodulin-dependent protein kinase II (CaMKII) was one of the key calcium regulatory genes shown to be upregulated in response to PZQ treatment (You *et al.*, 2013). Furthermore, the inhibition of CaMKII function in *Schistosoma* worms significantly improved the efficacy of PZQ, as shown by a considerable reduction in worm motility (You *et al.*, 2013). Extending this pivotal study, we explore here the use of selective and non-selective CaMK/kinase inhibitors to improve the efficacy of PZQ against juvenile and adult schistosomes *in vitro* and *in vivo*.

## Materials and methods

### Ethics statement

The conducts and procedures involving animal experiments were approved by the Animal Ethics Committee of the QIMR Berghofer Medical Research Institute (project number A0104-016), which adheres to the Australian code of practice for the care and use of animals for scientific purposes, as well as the Queensland Animal Care and Protection Act 2001; Queensland Animal Care and Protection Regulation 2002. This study was performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The Puerto Rican strain of *S. mansoni* was maintained in ARC out-bred Swiss female mice and *Biomphalaria glabrata* snails at the QIMR Berghofer Medical Research Institute from stocks originating from the National Institute of Allergy and Infectious Disease Schistosomiasis Resource Centre, Biomedical Research Institute (Rockville, Maryland, USA). General methods followed those previously published (Jones *et al.*, 2007; You *et al.*, 2009).

### Preliminary CaMK11 inhibitor assays with mechanically transformed *S. mansoni* schistosomula

*Schistosoma mansoni* cercariae were obtained by shedding infected *B. glabrata* under a bright light. Cercariae were transformed mechanically to schistosomula (Milligan and Jolly, 2011) and cultured in Basch's medium (Basch, 1981), with media changes every 3 days, depending on the age of schistosomula required. Schistosomula were dispensed into a 96-well flat bottom plate (100 schistosomula/well in 200  $\mu$ L of Basch's medium) and CaMK inhibitors with or without PZQ were added to each well to the required concentration.

The effects of 15 commercially available selective and non-selective CaMK inhibitors (Table 1) were assessed on 2- and 7-day-old schistosomula with or without the presence of PZQ.

All inhibitors were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, California, USA), or Selleckchem (Houston, Texas, USA). Inhibitory concentrations used were based on the IC<sub>50</sub>s reported by the manufacturer for each inhibitor for mammalian cells. Selective and non-selective CaMK inhibitors were tested at published mammalian 1  $\times$  IC<sub>50</sub> and 10  $\times$  IC<sub>50</sub> alone or in combination with the two PZQ concentrations over variable periods of exposure (4, 24 and 48 h). All the inhibitors were diluted in water or DMSO as indicated by the chemical suppliers (Table 1). PZQ was dissolved in DMSO.

Based on PZQ dosages provided by recent *in vitro* drug screening assays using newly transformed schistosomula (de Moraes *et al.*, 2012; Marxer *et al.*, 2012; Xiao *et al.*, 2018), a range of PZQ concentrations, 0.24–500  $\mu$ M, was tested during an initial screen for anti-schistosomal activity. From these *in vitro* assays, LD<sub>5</sub> and LD<sub>25</sub> of PZQ for 2-day schistosomula were chosen as the upper and lower concentrations, respectively, P1 (1  $\mu$ M) and P20 (20  $\mu$ M), for further studies.

Each treatment was performed in triplicate (separate wells), and the experiments were repeated three times; 24 h after treatment, the schistosomula were stained and fixed with 1:5 Trypan blue in 1% paraformaldehyde (in PBS) (Allison and Ridolpho, 1980) for 20–30 min. The parasites were washed until the well contents were clear, and the dead/damaged and unaffected schistosomula were counted under an inverted microscope at 100 magnification to calculate the percentage of dead/damaged schistosomula in each treatment group compared with the untreated control (1% DMSO in Basch's medium). A minimum of 100 parasites were counted in each treatment well.

**Table 1.** CaMK inhibitors used for initial *in vitro* screening of schistosomula

Candidate number	CaMK inhibitor name	Reported IC <sub>50</sub> for mammalian cells <sup>a</sup>	Solvent
1	KN-93	370 nM	DMSO
2	Staurosporine	20 nM	DMSO
3	Fasudil, Monohydrochloride Salt	1.9–5 $\mu$ M*	DMSO
4	Autocamtide-2-Related Inhibitory Peptide	40 nM	Water
5	1-Naphthyl PP1	22 $\mu$ M	DMSO
6	CaM Kinase II (290-309)	52 nM	Water
7	CaM Kinase II inhibitor	52 nM	Water
8	K-252a	3 nM	DMSO
9	KN-62	0.9 $\mu$ M	DMSO
10	Lavendustin C	0.2 $\mu$ M	DMSO
11	Autocamtide-2 inhibitor	40 nM	Water
12	K-252b	38 nM*	DMSO
13	HA-1077 dihydrochloride	1.9–15 $\mu$ M*	DMSO
14	Arcyriaflavin A	25 nM	DMSO
15	CaM Kinase II inhibitor	52 nM	Water

<sup>a</sup>Reported IC<sub>50</sub> as per manufacturer.

\*Activity against various kinases.

Based on the results of the preliminary *in vitro* assays, two kinase inhibitors, Staurosporine (STSP) and 1Naphthyl PP1 (1NAPP1) were chosen for further studies since they exhibited the most promising inhibitory effects against schistosomula.

### Quantification of the biochemical inhibition of CaMK II activity by selected inhibitors

A soluble worm antigen preparation (SWAP) was extracted from adult *S. mansoni* worms (You *et al.*, 2010) and its protein concentration quantified using the Bradford assay (Bio-Rad, Hercules, California, USA). The CaMKII activity of SWAP (0.028  $\mu$ g  $\mu$ L<sup>-1</sup>) with different concentrations of STSP (0.0025–1.28  $\mu$ M) or 1NAPP1 (2.75–1100  $\mu$ M) was quantified using CycLex CaM Kinase II Assay Kits (CycLex Co., Ltd. Nagano, Japan), according to the manufacturer's guidelines.

### Effects of CaMK inhibition on adult parasite motility

Adult *S. mansoni* worms were obtained by perfusion of infected mice (6–9 weeks old female Swiss), 6 weeks post cercarial challenge. Male and female adult worms were separated and cultured overnight in RPMI medium supplemented with 20% (v/v) Fetal Bovine Serum (FBS), and 1% (v/v) penicillin and streptomycin. The motility of adult worms before or after treatment was assessed using the xCELLigence system (Roche Inc., Basel, Switzerland) established in our laboratory as described (You *et al.*, 2013). Briefly, a single female or male adult worm was transferred individually into each well of a 96-well xCELLigence plate (ACEA Biosciences, San Diego, California, USA). RTCA controller software (Roche Inc.) was used to determine how the information was gathered from the xCELLigence plate. Each worm was cultured in 180  $\mu$ L of completed medium per well and motility was monitored every 15 s for 3 h to obtain a baseline motility reading (to identify healthy parasites) prior to the

addition of an inhibitor. STSP (0.2  $\mu\text{M}$ ) and 1NAPP1 (220  $\mu\text{M}$ ), with or without an  $\text{IC}_{50}$  of PZQ [as previously reported (Smout *et al.*, 2010)], were added to wells (six wells per treatment) and motility observed using the xCELLigence system over 24 h. Experiments performed with previously reported PZQ  $\text{IC}_{50}$  (188  $\text{ng mL}^{-1}$ ) dose reduced worm motility below 50% (Smout *et al.*, 2010), as compared to untreated controls. Similar reductions in motility were observed in groups treated with STSP and 1NAPP1 alone. A variation was evident between the effective concentration ( $\text{EC}_{50}$ ) for male and female adult worms. As a result, PZQ at a concentration of 37.6  $\text{ng mL}^{-1}$  (0.12  $\mu\text{M}$ ) ( $1/5 \times \text{IC}_{50}$  for *S. mansoni*) for male worms and 94  $\text{ng mL}^{-1}$  (0.3  $\mu\text{M}$ ) ( $1/2 \times \text{IC}_{50}$  for *S. mansoni*) for female worms, were used for subsequent experiments. STSP and 1NAPP1 were used at  $5 \times \text{IC}_{50}$  concentrations, 0.1 and 110  $\mu\text{M}$  respectively, for both male and female worms. Dead worms (heat killed) were included as immobile controls and exhibited 0% motility. Positive control worms were incubated in the presence of the DMSO concentration equivalent to that used for the highest drug concentration and represented 100% worm motility. Statistical analyses were undertaken using GraphPrism 5.0 (You *et al.*, 2013).

#### Biochemical activity of CaMKII in adult male and female worms exposed to 1NAPP1 and STSP with or without PZQ

After 24 h of inhibitor drug treatment, and following the motility assay, protein was extracted from male and female worms using 1% Triton X-100 in Tris-buffered saline supplemented with 1% (v/v) complete protease inhibitor cocktail (Tran *et al.*, 2010). CaMKII activity of the worm protein extract was measured in different treatment groups using the CycLex CaM Kinase II Assay Kit (CycLex Co.).

#### Mammalian cell cytotoxicity

Neonatal foreskin fibroblast (NFF), human hepatocellular carcinoma (HepG2), human hepatoma (Huh7) and mouse hepatocellular carcinoma (AML12) cell lines (from ATCC) were cultured in complete media as described (Boyle *et al.*, 2014) and were tested for the toxicity of varying concentrations of STSP (2000–0.002  $\mu\text{M}$ ) and 1NAPP1 (220–1.72  $\mu\text{M}$ ), with or without PZQ, using the sulforhodamine B (SRB) assay (Boyle *et al.*, 2014).

#### Initial in vivo treatment with PZQ to determine sub-therapeutic dosage against adult parasites

Three different PZQ dose regimens were used in 6–9-week-old female Swiss mice infected with 140 *S. mansoni* cercariae at 5 weeks post infection to determine a sub-therapeutic dose. The dosage threshold for the clearance of a patent *S. mansoni* infection from mice is considered as the therapeutic dose. PZQ was dissolved in 2.5% (v/v) cremophor EL (Sigma, St Louis, Missouri, USA) and given by oral gavage to three groups of mice ( $n = 3$ ) at a dose of 250  $\text{mg kg}^{-1} \text{day}^{-1}$  for 1 day; 250  $\text{mg kg}^{-1} \text{day}^{-1}$  for 3 days (total dose 750  $\text{mg kg}^{-1}$ ) and an escalating dose from 150–350  $\text{mg kg}^{-1}$  over 5 days (total dose 1250  $\text{mg kg}^{-1}$ ) (Chuah *et al.*, 2016). All the mice were perfused 49 days post-infection. Total male and female adult worm numbers were counted, and mouse livers were collected and processed for egg counts (Zhang *et al.*, 2011; Chuah *et al.*, 2016).

#### Dose escalation study of inhibitors

Optimum 1NAPP1 and STSP doses for mice were calculated using data obtained from *in vitro* assays, mammalian cytotoxicity assays and previously published data (Hill *et al.*, 1994; Abe *et al.*,

2001; Soskis *et al.*, 2012; Robichaux *et al.*, 2014). The full dosage for 1NAPP1 was 0.4  $\text{mg kg}^{-1}$  (approximate plasma concentration–22  $\mu\text{M}$ ) given by tail vein intravenous (*i.v.*) injection according to a previous study (Mizukami *et al.*, 2014). 1NAPP1 (1 mg) was first dissolved in 525  $\mu\text{L}$  DMSO, which was then diluted 10 times with 0.9% (v/v) saline (600  $\mu\text{M}$ ) (Mizukami *et al.*, 2014). The full dose of STSP was 10  $\text{mg kg}^{-1}$  (Hill *et al.*, 1994) given as a single dose by oral gavage. The concentration in the plasma of these mice was expected to reach  $\sim 40 \mu\text{M}$  given the bioavailability of 13% with similar compounds in a 30 g mouse (Hill *et al.*, 1994).

Dose escalation studies were carried out using 6–9-week-old female Swiss mice for the two inhibitors selected for further characterization. Mice were given 1/100th of the expected final dose and observed for a period of 7 days for any weight loss or development of any abnormal veterinary features. A second dose was given at the 1/10th of the expected final dose after 7 days to the same mice and monitored as above. A third dose was given at the standard expected dose and monitored as above. Tested at day 3 and day 7 post treatment, both the alanine transaminase (ALT) and aspartate transaminase (AST) colour endpoint assays (BioScientific, Max Discovery™, Austin, Texas, USA) were used to determine changes in liver enzymes as indicators of hepatotoxicity.

#### Combination of PZQ and CaMK inhibitors in in vivo trials


Three animal trials were conducted as follows. Six-week-old female outbred Swiss mice were used for *in vivo* experiments to determine the efficacy of the inhibitor and PZQ treatment of *S. mansoni*-infected animals. Trials 1 and 2 were carried out to test the efficacy of the selected inhibitors with/without PZQ and PZQ only. Each trial had three treatment groups depending on the time point of treatment post-cercarial challenge chosen. The time points for drug treatment were either on day 2 post-infection, day 7 post-infection or week 5 post-infection, corresponding to the targeting of day 2 or day 7 schistosomula or adult parasites. There were six groups in trial 1 and 2 including the control (no treatment), PZQ only, STSP only, 1NAPP1 only, PZQ/STSP and PZQ/1NAPP1. There were five mice/group in trial 1 and eight mice/group in trial 2. Mice were infected with 140 cercariae/mouse in trial 1 and 100 cercariae/mouse in trial 2. In trial 3, all mice (10 mice/group) were infected with 80 cercariae/mouse and the effect of three different STSP doses was tested in combination with PZQ given at 5 weeks post-infection.

1NAPP1 was reconstituted as described above and given 0.4  $\text{mg kg}^{-1} \text{day}^{-1}$  *i.v.* per mouse in trial 1 (plasma concentration,  $\sim 22 \mu\text{M}$ , which is closer to the  $\text{IC}_{50}$ , because of the requirement for intravenous administration and to prevent possible toxicity) (Soskis *et al.*, 2012; Robichaux *et al.*, 2014) and increased to 0.6  $\text{mg kg}^{-1} \text{day}^{-1}$  in trial 2 (plasma concentration,  $\sim 33 \mu\text{M}$ ) to achieve the required plasma concentrations.

STSP was given at the same dose of 10  $\text{mg kg}^{-1} \text{day}^{-1}$  as a single oral gavage (approximate plasma concentration 40  $\mu\text{M}$ ) in both trial 1 and trial 2. In trial 3, different doses of STSP (2.5, 5 and 10  $\text{mg kg}^{-1} \text{day}^{-1}$  as a single dose) were given in combination with PZQ to each group.

PZQ was given orally at a dose of 250  $\text{mg kg}^{-1}$  dissolved in 2.5% (v/v) cremophor EL (Chuah *et al.*, 2016). The control group was given 2.5% (v/v) cremophor EL orally and 10% DMSO in 0.9% (v/v) saline *i.v.* In the groups treated with STSP/PZQ by oral gavage, there was a 45 min interval between the two doses to reduce potential interactions between the drugs or solvents in the stomach.

Feces were collected from individual mice at 6 weeks post-infection in all groups before worm perfusion at 7 weeks



**Fig. 1.** *In vitro* lethality effect of CaMK11 inhibitors, with and without praziquantel on *S. mansoni* juvenile parasites. (A) *In vitro* 2-day-old schistosomula. (B) *In vitro* 7-day-old schistosomula. The x-axis lists the CaMK inhibitors (see Table 1 for candidate number and corresponding compounds), used at low concentration (a concentration corresponding to those of published mammalian  $IC_{50}$  levels), indicated by the inhibitor number alone, or at high concentration (10x mammalian  $IC_{50}$ ) designated by an 'H', or no inhibitors = 0. Columns refer to PZQ concentrations P0 = no PZQ, P1 =  $1 \mu M$  ( $0.312 \mu g mL^{-1}$ ), P20 =  $20 \mu M$  ( $6.25 \mu g mL^{-1}$ ). The bottom dotted line shows the average numbers of dead parasites observed in non-treated controls (without PZQ or CaMK inhibitor). The top dotted line shows the average maximum % death achieved by PZQ alone without any CaMK inhibitor. Note in panel B that both dotted lines are at similar levels. Bars indicate s.e.m.  $n = 3$ .

post-infection. Feces was fixed in 10% formalin and processed for egg counting as described previously (Zhang *et al.*, 2011). Total and female adult worm numbers were counted and then fixed in 10% (v/v) buffered formalin. Mouse livers were collected and processed for egg counting (Zhang *et al.*, 2011; Chuah *et al.*, 2016).

All data were analysed using GraphPad Prism 7.02. The group means were compared between each other using the Kruskal-Wallis test.

#### Real-time PCR of selected calcium signalling genes

Total RNA was isolated (Hoffmann *et al.*, 2002) from adult male and female *S. mansoni* worms, respectively, treated with STSP and 1NAPP1 with or without PZQ. All samples were DNase treated (Promega, Madison, Wisconsin, USA) prior to cDNA synthesis (Gobert *et al.*, 2009) using Quantitect Reverse Transcription kits (Qiagen Inc.). The expression levels of selected key genes involved in the calcium-mediated signalling pathways (Table S2) were tested on the worm cDNA samples using real-time PCR (Moertel *et al.*, 2008). Tubulin  $\alpha$  (Araujo-Montoya *et al.*, 2011) was used as the reference gene. All other primers were designed using Primer3 web version 4.0.0 online software. qPCR was performed using SYBR Green master mix (Thermo Fisher Scientific) on a Corbett Rotor Gene 6000 (Corbett Life Sciences). Rotor-Gene 6000 Series software (version 1.7) and GraphPad Prism (version 7.02) were used to analyse the data, using the standard curve method as described (Gobert *et al.*, 2009).


## Results

### CaMKII inhibitor assays with mechanically transformed *S. mansoni* schistosomula

The numbers of live/dead schistosomula were counted (dead parasites absorb the blue stain) using the trypan blue exclusion staining method as described (Pinto *et al.*, 2011) to determine the impact of CaMK inhibitors on schistosomula viability.

Figure 1 shows a summary of responses of 2-day-old (Fig. 1A) and 7-day-old (Fig. 1B) schistosomula to all the selected CaMK inhibitors 24 h post-treatment. Schistosomula treated with 1NAPP1 (candidate 5) demonstrated  $\geq 50\%$  death rates in the 2- and 7-day-old groups with or without PZQ. However, there was no significant difference in the response of day 2 and day 7 schistosomula to NAPP1 except when combined with the higher dose of PZQ. STSP (candidate 2) combined with PZQ resulted in  $\geq 50\%$  death rates with 2-day-old schistosomula only.

Further testing of STSP with 7-day-old schistosomula, at 4, 24 and 48 h after treatment confirmed the findings presented in Fig. 1B (Fig. 2C, D, G, H, K and L). With 2-day-old schistosomula (Fig. 2A, B, E, F, I and J), an effect with STSP was evident in the 24 h post treatment group, reaching 50% death rate at a concentration of  $0.02 \mu M$  in combination with  $20 \mu M$  PZQ. The published  $IC_{50}$  for STSP for mammalian cells is also the same as the  $LD_{50}$  for the 2-day-old schistosomula observed here (Fig. 2E). At 48 h there was a further increase in the death rates of schistosomula. The STSP and  $20 \mu M$  PZQ combination group always showed higher death rates followed by the STSP and  $1 \mu M$  PZQ group.



**Fig. 2.** *In vitro* effect of STSP and 1NAPP1 on 2-day (A, B, E, F, I, J) and 7-day (C, D, G, H, K, L) old *S. mansoni* schistosomula at 4 h (A–D), 24 h (E–H) and 48 h (I–L) post treatment. The x-axis shows CaMK inhibitor concentrations, where 0 shows PZQ only treatment. P0 = CaMK inhibitor alone without PZQ, P1 = CaMK inhibitor with 1  $\mu\text{M}$  (0.312  $\mu\text{g mL}^{-1}$ ) PZQ, P2 = CaMK inhibitor with 20  $\mu\text{M}$  (6.25  $\mu\text{g mL}^{-1}$ ) PZQ.  $n = 3$ . STSP = Staurosporine, 1 NAAP1 = 1-Naphthyl PP1.

Increasing STSP concentration to 0.4  $\mu\text{M}$  brought the death rates closer to the PZQ/STSP combined groups (Fig. 2E).

1NAPP1 showed detrimental effects on 7-day-old schistosomula alone or in combination with PZQ, starting from a concentration of 22  $\mu\text{M}$  (published mammalian  $\text{IC}_{50}$ ) (Fig. 2D, H and L). Similar effects were evident on 2-day-old schistosomula (Fig. 2B, F and J) except for the combination group with 20  $\mu\text{M}$  PZQ, where PZQ alone showed a 20–40% death rate over the 24–48 h period. This trend was also observed in the STSP-treated groups due to the moderate efficacy of PZQ against schistosomula up to 3 days (Fig. 2E and I). 1NAPP1 achieved a 100% death rate at a concentration of 220  $\mu\text{M}$  ( $10 \times \text{IC}_{50}$ ) with or without PZQ in both day 2- and day 7-old schistosomula.

#### Quantification of the reduction of CaMKII activity by the selected inhibitors

STSP at a concentration of 0.04  $\mu\text{M}$  was able to inhibit circa 50% of the CaMKII activity in *S. mansoni* SWAP, whereas 1NAPP1 reached 50% inhibition at around a concentration of 660  $\mu\text{M}$ . STSP had a lower  $\text{IC}_{50}$  than 1NAPP1 when tested *in vitro* (Fig. S1).

#### Motility of *S. mansoni* male and female worms following drug treatment

To ensure the worms used for drug treatment were alive, motility of all the worms was measured by xCELLigence for 3 h before the addition of any drug. There were no significant differences ( $P$  value  $> 0.05$ ) in motility among the groups for either females or males prior to the introduction of the drugs. The range of motility (% relative to untreated worms) was 70–92% for females and 85–110% for males (Fig. 3A and B) at the commencement of the experiment. Female worms treated with STSP and 1NAPP1 alone regained 100% motility after 48 h incubation (Fig. 3C). Motility of females treated with the PZQ/STSP and PZQ/1NAPP1 combinations decreased to 40% and 35%, respectively; however, there was no significant decline compared with female

worms treated with PZQ only ( $P > 0.05$ ). The motility of male *S. mansoni* was reduced significantly ( $P \leq 0.05$ ) after 48 h treatment with either the PZQ/STSP (31%) or PZQ/1NAPP1 (25%) combination compared with PZQ-treated males (Fig. 3D).


#### Testing CaMK II activity in adult male and female *S. mansoni* exposed to 1NAPP1 and STSP with or without PZQ

*Schistosoma mansoni* males treated with STSP alone or in combination with PZQ had significantly reduced CaMKII activity compared with those treated with PZQ alone, measured using the CycLex CaM Kinase II Assay Kit. Males treated with STSP showed a significant reduction (77%,  $P = 0.02$ ) in CaMKII activity compared with those treated with 1NAPP1 (Fig. 4A). This outcome supported the results of the *in vitro* assays performed with SWAP (Fig. S1) and showed that STSP was a better inhibitor of CaMKII both *in vitro* and *in vivo*. STSP was superior to 1NAPP1 in suppressing CaMKII activity both in males and females, although the response with both inhibitors was less pronounced in female worms. This was representative of the increased reduction in motility in males than in females, as shown in the xCELLigence analysis (Fig. 3). PZQ treatment did not seem to affect CaMKII function as CaMK activity was similar to that of the untreated control group.


Reciprocal changes were observed in CaMKII gene copy numbers, calculated using real-time PCR, showing significantly higher levels of transcription in males (except in the PZQ-only and STSP-only treatment groups) than in females ( $P = 0.006–0.287$ ), likely as a result of possible attempts to upregulate CaMKII production.

#### Real-time PCR

Overall, transcription of the RYR 1, PHK1 and PKC4 genes was significantly lower in female worms, including the untreated controls (Fig. 5), which was also evident in CaMKII expression levels (Fig. 4B). However, the same trend was not evident in the transcription of IP33K2 for most of the groups. RYR1 and PKC4



**Fig. 3.** Effect of CaMK inhibitors on the motility of adult male and female *S. mansoni* worms. Motility (%) is presented on the left y-axis while the corresponding *P* value (comparing motility of worms treated with PZQ and PZQ/STSP) is presented on the right y-axis. Motility (%) of female (A) and male (B) *S. mansoni* worms 3 h prior to treatment are shown in the left panel. Error bars (s.e.m.) are shown at time points 0, 1, 2 and 3 h. Motility (%) of female (C) and male (D) *S. mansoni* worms, after being exposed for 48 h to STSP and 1NAPP1 with or without PZQ are shown in the right panel. Error bars (s.e.m.) are shown in (C) and (D) every 8 h after treatment;  $n = 6$ . PZQ = Praziquantel; STSP = Staurosporine; 1NAPP1 = 1-Naphthyl PP1.



**Fig. 4.** CaMK expression and activity assays in male (M) and female (F) *S. mansoni* worms treated with various combinations of STSP, 1NAPP1 and PZQ compared to untreated parasites (control). (A) CaMK II enzyme activity in *S. mansoni* male (M) and female (F) worms treated with various combinations of STSP, 1NAPP1 and PZQ expressed as folds relative to control. Control = 1. (B) Quantitative real-time PCR analysis of CaMKII gene expression levels in different treated groups compared to untreated male and female worms (control). Error bars represent s.e.m.  $N = 3$ . STSP = Staurosporine, 1NAPP1 = 1-Naphthyl PP1.

expression was significantly reduced ( $P \leq 0.05$ ) following treatment with PZQ + STSP in female worms compared with the PZQ-treated group. A similar trend occurred in the expression of PKC4, PHK1 and IP33K2 in male worms treated with PZQ + STSP ( $P \leq 0.05$ ) showing the effect of CaMKII inhibition on related genes in the calcium signalling pathway.


#### Mammalian cell cytotoxicity with CamK inhibitors and PZQ

A summary of  $LD_{50}$ s calculated following the cytotoxicity assays is presented in Table 2. Detailed dose-response curves are shown in Supplementary Figs S2–S4. AML, Huh7 and NFF showed variable

toxicity to 1NAPP1 and STSP. STSP was more toxic to AML ( $LD_{50} = 0.001 \mu M$ ) and NFF ( $LD_{50} = 0.821 \mu M$ ) than 1NAPP1 ( $LD_{50} = 52.7$  and  $>100 \mu M$ ) but less toxic to Huh7.

#### Dose escalation study

Sub-therapeutic dose level of PZQ  $250 \text{ mg kg}^{-1}$  was selected to be combined with CaMK inhibitors in the trials as there was a 43% reduction in adult worm numbers obtained from mice treated with PZQ ( $250 \text{ mg kg}^{-1}$  dose) when compared to worms perfused from untreated controls; liver egg burdens showed a similar trend but the reduction in numbers (60%) was slightly higher (Fig. S5).



**Fig. 5.** Quantitative real-time PCR analysis of the expression of selected gene in the calcium signalling pathway in *S. mansoni* male (M) and female (F) worms treated with various combinations of STSP, 1NAPP1 and PZQ compared to untreated male and female worms (control M and control F). Bars indicate s.e.m.; n = 3. (A) RYR1; (B) PHK1; (C) PKC4; (D) IP33K2.

**Table 2.** LD<sub>50</sub>s calculated by mammalian cell cytotoxicity assays

Treatment	LD <sub>50</sub> in $\mu\text{M}$ for different cell types			Published IC <sub>50</sub> for mammalian cells
	AML 12	Huh 7	NFF	
1NAPP1	52.780	1.448 e + 016	>100	22 $\mu\text{M}$
1NAPP1 + PZQ	62.530	0.352	>100	
STSP	0.001	>100	0.821	0.02 $\mu\text{M}$
STSP + PZQ	0.002	>100	0.461	

The reported normal range in female Swiss mice for ALT activity is 24–193 IU L<sup>-1</sup> and for AST activity is 46–244 IU L<sup>-1</sup> (Serfilippi *et al.*, 2003). The liver enzymes tested were within the reported normal range for both day 3 and day 7 post-treatment, for all treatment groups, showing no hepatotoxicity with the doses tested. However, with STSP the day 3 enzyme levels were marginally elevated compared to day 7 (Fig. S6).

**In vivo trials**


In trial 1, mice treated with PZQ alone on the second day post-infection (Fig. 6A, B and C) did not result, at perfusion, in any statistically significant reduction in *S. mansoni* worm or egg counts compared to the untreated mice. However, treatment with STSP alone resulted in significant reductions in worm numbers (33%,  $P \leq 0.05$ ), liver eggs (46%,  $P \leq 0.01$ ) and fecal eggs (83%,  $P \leq 0.05$ ) compared with untreated control mice. The combined PZQ/STSP group had a significant reduction in liver egg counts compared to the PZQ group. The second trial did not replicate the findings except for the PZQ/STSP combined group which showed significant fecal egg reduction (85%,  $P \leq 0.05$ ) compared to the control group (Fig. 7C).

During the PZQ insusceptible period (group treated on the seventh day post-infection) mice treated with the PZQ/1NAPP1

combination resulted in significant reductions in total worms in both trial 1 and trial 2 (Figs 6D and 7D) and liver eggs reduction in trial 1. The group treated with STSP alone showed a significant liver egg count reduction in trial 1 (Fig. 6E). However, treatment of mice with PZQ alone also, unexpectedly, showed a significant reduction in total worm numbers in trial 2 and liver egg reductions in both trial 1 and trial 2. In the group treated at week 5 post-infection (mature adult worms present), there was a significant reduction in the liver egg burden compared to the control in all groups except for those treated with 1NAPP1 and STSP alone in trial 1 (Fig. 6H). Similar results were evident in trial 2 with the STSP-treated group also showing a significant egg reduction (Fig. 7H). In trial 2, all groups showed significant reductions in fecal egg burdens when compared to the control (Fig. 7I) except for the group treated with 1NAPP1 alone, a trend not evident in trial 1. Of note, the fecal egg count in the STSP-treated group was significantly lower than the PZQ group (94%,  $P \leq 0.05$ ) (Fig. 7I), indicating a potential role for STSP in inhibiting the fecundity of *S. mansoni*. Although not significant, the groups treated with a combination of PZQ and CaMK inhibitor had low numbers of fecal eggs when compared to the group treated with PZQ alone in both trial 1 and 2. Total worm numbers and liver eggs were significantly reduced in the PZQ/STSP combination group in both trials compared to controls. There was a significant reduction in total worm numbers in the groups treated with the PZQ/CaMK inhibitor combination (69%, 86%) and PZQ alone (77%) in trial 1 compared to controls; this was only replicated in the PZQ/STSP group (87%) in trial 2.

**In vivo mouse trial using combinations of PZQ and STSP treatments**

Trial 3 tested the effect of three different doses of STSP combined with PZQ, at 5 weeks post infection, in groups of 10 mice infected with 80 cercariae per mouse. All the treatment groups showed significant reductions in worm and egg counts compared with the untreated control group (Fig. 8). The group treated with the highest dose of STSP had the highest reduction in worm and egg



**Fig. 6.** Mouse trial 1: *in vivo* effects of PZQ, STSP, 1NAPP1 and inhibitor/PZQ combinations in a *S. mansoni* mouse model. Treatments were provided either 2 days (A, B, C), 7 days (D, E, F) or 5 weeks (G, H, I) post cercarial challenge and parasitological parameters were taken from sacrificed animals 6 weeks post cercarial challenge. The numbers of worms, liver eggs and faecal eggs are presented. STSP = Staurosporine, 1NAPP1 = 1-Naphthyl PP1. Bars indicate s.e.m.;  $n = 5$ .  $P$  values \* $\leq 0.05$ , \*\* $\leq 0.01$ , \*\*\* $\leq 0.001$ .

counts compared with the control group and had significantly lower (58%) liver egg counts compared with the PZQ group.

## Discussion


PZQ action in schistosomes is dependent on parasite age, with some stages being refractory to treatment. This limits the effectiveness of a single day treatment regime. PZQ has limited efficacy against very young schistosomes [ $< 3$  days post cercarial infection (pci)] and older schistosomes (28 day pci), where 10X to 30X the dose of PZQ is needed to kill compared to the adult stage (Pica-Mattocchia and Cioli, 2004; Xiao *et al.*, 2010); PZQ is inactive against 3–21-day worms, and fully active against the sexually mature blood flukes (Xiao *et al.*, 2010). Therefore, we investigated 2-day-old schistosomes in order to focus on a developmental stage with a limited sensitivity period and 7-day-old schistosomes, which are insensitive to PZQ, to test the effects of 15 different CaMKII (selective and non-selective) inhibitors on parasite survival. Given the considerable numbers of parasites required to achieve statistical power and, consequently, the extremely large number of animals needed to provide such worm numbers, with potential animal ethics concerns, mechanically produced schistosomes have generally been used as a high throughput tool for phenotypic pre-screening in drug efficacy studies (de Moraes *et al.*, 2012; Tekwu *et al.*, 2016), a trait followed here.

Mechanically transformed schistosomes are commonly used for drug screening assays. The concentration of  $1 \mu\text{M}$  PZQ used in this study is comparable to those used in previous studies ( $1.5 \mu\text{M}$  *S. haematobium*;  $0.7 \mu\text{M}$  *S. mansoni* schistosomes) (Marxer *et al.*, 2012). In another study (de Moraes *et al.*, 2012),


PZQ at  $20 \mu\text{M}$  was used to treat *S. mansoni* schistosomes, justifying drug dosages given in the current study, furthermore the refractory nature of *in vitro* schistosomes to PZQ was also noted. In a recent review by Xiao *et al.*, the use of *in vitro* parasites and PZQ dosages between 3 and  $30 \mu\text{M}$  is reported (Xiao *et al.*, 2018).

A range of commercially available CaMKII (selective and non-selective) inhibitors were tested on PZQ-sensitive (2-day-old) and PZQ-insensitive (7-day-old) schistosomes to select the most effective inhibitors. In *in vitro* assays, we were able to select STSP and 1NAPP1, which exhibited the highest level of killing of schistosomes at 2- and 7-day-old tested, in the presence or absence of PZQ. Although not selective, 1NAPP1 was a stronger CaMK inhibitor for both day 2 and day 7 schistosomes, but STSP better reduced both CaMK activity in *S. mansoni* adult protein extracts (SWAP) and the motility of live male worms *in vitro*. However, the motility of male worms was significantly decreased following treatment with STSP combined with PZQ compared with those exposed to either of these compounds. This result is supported by our previous study (You *et al.*, 2013) when CaMKII transcription was reduced by RNAi with 50–69% in adult *S. japonicum* with the result that the subsequent effect of an IC<sub>50</sub> dosage of PZQ was exacerbated, exhibiting decreased motility from 47–61% to 23–27% in adult worms. It has been reported that PZQ disrupts  $\text{Ca}^{2+}$  homeostasis in adult schistosomes by an unknown mechanism (Cioli and Pica-Mattocchia, 2003). Our previous investigations further indicate that CaMKII moderates the effects of PZQ through stabilizing  $\text{Ca}^{2+}$  fluxes within schistosome muscle and tegument. One hypothesis might be that PZQ action involves an increase of intracellular





**Fig. 7.** Mouse trial 2: *in vivo* effects of PZQ, STSP, 1NAPP1 and inhibitor/PZQ combinations in a *S. mansoni* mouse model. Treatments were provided either 2 days (A, B, C), 7 days (D, E, F) or 5 weeks (G, H, I) post cercarial challenge and parasitological parameters were taken from sacrificed animals 6 weeks post cercarial challenge. The numbers of worms, liver eggs and faecal eggs are presented. STSP = Staurosporine, 1 NAPP1 = 1-Naphthyl PP1. Bars indicate s.e.m.;  $n = 8$ .  $P$  values \* $\leq 0.05$ , \*\* $\leq 0.01$ , \*\*\* $\leq 0.001$ .



**Fig. 8.** Mouse trial 3: *in vivo* effects of three varying concentrations of STSP (2.5, 5 and 10 mg kg<sup>-1</sup>) in conjunction with PZQ (250 mg kg<sup>-1</sup>) in a *S. mansoni* mouse model. Treatments were provided on 5 weeks post-cercarial challenge and parasitological parameters were taken from sacrificed animals 6 weeks post-cercarial challenge. The numbers of worms, liver eggs and faecal eggs are presented. STSP = Staurosporine. Bars indicate s.e.m.;  $n = 10$ .  $P$  values \* $\leq 0.05$ , \*\* $\leq 0.01$ , \*\*\* $\leq 0.001$ , \*\*\*\* $\leq 0.0001$ .

Ca<sup>2+</sup> with CamKII acting to maintain Ca<sup>2+</sup> homeostasis as potentially central to the mode of action of PZQ (You *et al.*, 2015; Nawaratna *et al.*, 2018).

In addition, as was evident from the *in vitro* assays, STSP and 1NAPP1 had better treatment efficacy on 2-day-old schistosomula in the first mouse trial compared with controls. Seven-day-old schistosomula showed less response *in vivo* to either of the inhibitors, as expected, when compared with initial

*in vitro* assays. However, PZQ/1NAPP1 treatment was a more effective combination against 7-day-old schistosomula, which was confirmed in the second mouse trial. Therefore, 1NAPP1 might represent a superior adjunct therapy to be used with PZQ during the PZQ-insusceptible period. Adult worms showed a better response consistently through all three mouse drug trials to STSP alone or to PZQ/STSP and the PZQ/1NAPP1 combination *in vivo* compared with untreated controls. However,

increasing the 1NAPP1 dose by 1.5 times in trial 2 did not improve the results.

In trial 1, there was a significant worm and egg reduction in mice treated at 5 weeks post infection with the PZQ/STSP or PZQ/NAPP1 combination, due to the rapid killing of worms. This was reflected in the significantly decreased motility of adult *S. mansoni* *in vitro* after being treated with PZQ/PZQ/STSP or PZQ/NAPP1 compared with PZQ-treated worms.

STSP, which is a microbial alkaloid isolated from *Streptomyces staurosporeus* (Park *et al.*, 2013), has been investigated as an anticancer therapy in clinical trials (Eder *et al.*, 2004; Monnerat *et al.*, 2004). STSP has been administered at an oral dose of 5–10 mg kg<sup>-1</sup> day<sup>-1</sup> (Abe *et al.*, 2001), intraperitoneally or subcutaneously (Hill *et al.*, 1994) in mice. The inability to mount a similar response in killing parasites *in vivo* could be due to many reasons. STSP was given orally to mice with or without PZQ. Although an oral route is less intrusive than the intravenous route, pharmacokinetic interactions in the stomach, variability in absorption and first pass metabolism are some of the major factors that might have affected the final effective plasma concentration of the drug. Gastric emptying in mice shows an exponential decay with 50% emptying around 30 min (Schwarz *et al.*, 2002); therefore, we spaced the PZQ and STSP doses 45 min apart to prevent possible drug and solvent interactions in the stomach but, on the other hand, to reach high plasma concentrations around the same time. PZQ absorption in humans is known to be 80% of the oral dose with a plasma half-life of 1–2 h (Andrews *et al.*, 1983; Chai, 2013). Both STSP and PZQ have limited bioavailability (13% and 5%, respectively) (Hill *et al.*, 1994; Abila *et al.*, 2017). Although adult worms may be initially exposed to a drug concentration similar to that received by oral administration in the mesenteric veins before reaching the liver, the drug exposure of schistosomula, which reside in the lungs, will be affected due to drug clearance before the worms reach the lungs. The discrepancies between the *in vitro* and *in vivo* assays could also be explained by the use of mechanically transformed schistosomula rather than naturally transformed schistosomula *in vivo*.

In trials 1 and 2, the treatment at week 5 post-infection, with the highest published doses of STSP (10 mg kg<sup>-1</sup>) combined with PZQ (250 mg kg<sup>-1</sup>), reached the maximum effect in terms of reductions in worm burden and egg counts compared with the control group. Reduced STSP doses used in trial 3 (2.5 and 5 mg kg<sup>-1</sup>) on adult worm infections, however, yielded lower worm and egg reductions. Mice treated with PZQ/STSP10 (STSP 10 mg kg<sup>-1</sup> with PZQ 250 mg kg<sup>-1</sup>) on week 5 post-infection showed a similar worm reduction, but significantly lower liver egg counts (58%) compared with the PZQ group, indicating the additive effect of STSP in inhibiting the fecundity or egg production of adult parasites.

We have shown that the inhibition of CaMK can be used as a possible adjunct therapy to PZQ in treating juvenile and adult schistosome infections. The *in vivo* experiments, however, did not show the effects in a similar magnitude to the *in vitro* results. The experiments could be repeated with different solvents to improve the efficacy of drug delivery. According to the *in vitro* results, the STSP and 1NAPP1 dose could be further reduced to establish whether similar results would be obtained using the schistosomula stage, which would help to minimize any possible drug side effects. The more selective CaMK inhibitors K-252a (inhibitor 8) and Autocamtide-2 inhibitor (inhibitor 11) could be possible additional candidates for future combination treatment trials. A wider range of inhibitor concentrations/doses could be tested in future follow-up studies with separate control group for each solvent used. To confirm the functional effects of CaMK inhibitors on calcium homeostasis in worms, the development of a live worm staining technique to detect calcium

influx could be used in future studies to yield more phenotypic data to explore the impact of combined drug treatments on schistosomes.

**Supplementary material.** The supplementary material for this article can be found at <https://doi.org/10.1017/S0031182020001250>.

**Acknowledgements.** We gratefully acknowledge the assistance given by Mary Duke in animal experiments. The support of the QIMRB animal facility is also appreciated.

**Financial support.** This research was funded by the National Health and Medical Research Council (NHMRC) of Australia. DPM is an NHMRC Senior Principal Research Fellow and Senior Scientist at QIMRB.

**Conflict of interest.** The authors declare no conflicts of interest.

**Ethical standards.** The conducts and procedures involving animal experiments were approved by the Animal Ethics Committee of the QIMRB Berghofer Medical Research Institute (project number A0104-016), which adheres to the Australian code of practice for the care and use of animals for scientific purposes, as well as the Queensland Animal Care and Protection Act 2001; Queensland Animal Care and Protection Regulation 2002. This study was performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.

## References

- Abe S, Kubota T, Otani Y, Furukawa T, Watanabe M, Kumai K, Akiyama T, Akinaga S and Kitajima M (2001) UCN-01 (7-hydroxystaurosporine) inhibits *in vivo* growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery. *Japanese Journal of Cancer Research* **92**, 537–545.
- Abla N, Keiser J, Vargas M, Reimers N, Haas H and Spangenberg T (2017) Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the *Schistosoma mansoni* mouse model. *PLoS Neglected Tropical Diseases* **11**, e0005942.
- Allison DC and Ridolphi P (1980) Use of a trypan blue assay to measure the deoxyribonucleic acid content and radioactive labeling of viable cells. *Journal of Histochemistry and Cytochemistry* **28**, 700–703.
- Andrews P, Thomas H, Pohlke R and Seubert J (1983) Praziquantel. *Medicinal Research Reviews* **3**, 147–200.
- Araujo-Montoya BO, Rofatto HK, Tararam CA, Farias LP, Oliveira KC, Verjovski-Almeida S, Wilson RA and Leite LC (2011) *Schistosoma mansoni*: molecular characterization of Alkaline Phosphatase and expression patterns across life cycle stages. *Experimental Parasitology* **129**, 284–291.
- Basch PF (1981) Cultivation of *Schistosoma mansoni* *in vitro*. I. Establishment of cultures from cercariae and development until pairing. *Journal of Parasitology* **67**, 179–185.
- Boyle GM, D'Souza MM, Pierce CJ, Adams RA, Cantor AS, Johns JP, Maslovskaya L, Gordon VA, Reddell PW and Parsons PG (2014) Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse models. *PLoS ONE* **9**, e108887.
- Chai JY (2013) Praziquantel treatment in trematode and cestode infections: an update. *Infection & Chemotherapy* **45**, 32–43.
- Chuah C, Jones MK, McManus DP, Nawaratna SK, Burke ML, Owen HC, Ramm GA and Gobert GN (2016) Characterising granuloma regression and liver recovery in a murine model of *Schistosomiasis japonica*. *International Journal for Parasitology* **46**, 239–252.
- Cioli D and Pica-Mattoccia L (2003) Praziquantel. *Parasitology Research* **90** (Supp 1), S3–S9.
- Day TA, Bennett JL and Pax RA (1992) Praziquantel: the enigmatic antiparasitic. *Parasitology Today* **8**, 342–344.
- de Moraes J, Nascimento C, Yamaguchi LF, Kato MJ and Nakano E (2012) *Schistosoma mansoni*: *in vitro* schistosomicidal activity and tegumental alterations induced by pipartine on schistosomula. *Experimental Parasitology* **132**, 222–227.
- Doenhoff MJ, Cioli D and Utzinger J (2008) Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. *Current Opinion in Infectious Diseases* **21**, 659–667.
- Eder JP Jr, Garcia-Carbonero R, Clark JW, Supko JG, Puchalski TA, Ryan DP, Deluca P, Wozniak A, Campbell A, Rothermel J and LoRusso P

- (2004) A phase I trial of daily oral 4'-N-benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies. *Investigational New Drugs* **22**, 139–150.
- Gobert GN, McManus DP, Nawaratna S, Moertel L, Mulvenna J and Jones MK** (2009) Tissue specific profiling of females of *Schistosoma japonicum* by integrated laser microdissection microscopy and microarray analysis. *PLoS Neglected Tropical Diseases* **3**, e469.
- Greenberg RM** (2005) Ca<sup>2+</sup> signalling, voltage-gated Ca<sup>2+</sup> channels and praziquantel in flatworm neuromusculature. *Parasitology* **131**(Suppl), S97–S108.
- Hill DL, Tillery KF, Rose LM and Posey CF** (1994) Disposition in mice of 7-hydroxystaurosporine, a protein kinase inhibitor with antitumor activity. *Cancer Chemotherapy and Pharmacology* **35**, 89–92.
- Hoffmann KF, Johnston DA and Dunne DW** (2002) Identification of *Schistosoma mansoni* gender-associated gene transcripts by cDNA microarray profiling. *Genome Biology* **3**, 0041.1–0041.12.
- Hotez PJ and Fenwick A** (2009) Schistosomiasis in Africa: an emerging tragedy in our new global health decade. *PLoS Neglected Tropical Diseases* **3**, e485.
- Jones MK, McManus DP, Sivadurai P, Glanfield A, Moertel L, Belli SI and Gobert GN** (2007) Tracking the fate of iron in early development of human blood flukes. *International Journal of Biochemistry & Cell Biology* **39**, 1646–1658.
- Lo NC, Addiss DG, Hotez PJ, King CH, Stothard JR, Evans DS, Colley DG, Lin W, Coulibaly JT, Bustinduy AL, Raso G, Bendavid E, Bogoch II, Fenwick A, Savioli L, Molyneux D, Utzinger J and Andrews JR** (2017) A call to strengthen the global strategy against schistosomiasis and soil-transmitted helminthiasis: the time is now. *The Lancet. Infectious Diseases* **17**, e64–e69.
- Marxer M, Ingram K and Keiser J** (2012) Development of an *in vitro* drug screening assay using *Schistosoma haematobium* schistosomula. *Parasites & Vectors* **5**, 165.
- McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ and Zhou XN** (2018) Schistosomiasis. *Nature Reviews Disease Primers* **4**, 13.
- Milligan JN and Jolly ER** (2011) Cercarial transformation and *in vitro* cultivation of *Schistosoma mansoni* schistosomules. *Journal of Visualized Experiments* **54**, e3191.
- Mizukami J, Sato T, Camps M, Ji H, Rueckle T, Swinnen D, Tsuboi R, Takeda K and Ichijo H** (2014) ASK1 Promotes the contact hypersensitivity response through IL-17 production. *Scientific Reports* **4**, 4714.
- Moertel L, Gobert GN and McManus DP** (2008) Comparative real-time PCR and enzyme analysis of selected gender-associated molecules in *Schistosoma japonicum*. *Parasitology* **135**, 575–583.
- Monnerat C, Henriksson R, Le Chevalier T, Novello S, Berthaud P, Faivre S and Raymond E** (2004) Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer. *Annals of Oncology* **15**, 316–323.
- Nawaratna SSK, You H, Jones MK, McManus DP and Gobert GN** (2018) Calcium and Ca(2+)/calmodulin-dependent kinase II as targets for helminth parasite control. *Biochemical Society Transactions*. doi:10.1042/BST20180480.
- Park BS, Abdel-Azeem AZ, Al-Sanea MM, Yoo KH, Tae JS and Lee SH** (2013) Staurosporine analogues from microbial and synthetic sources and their biological activities. *Current Medicinal Chemistry* **20**, 3872–3902.
- Pica-Mattoccia L and Cioli D** (2004) Sex- and stage-related sensitivity of *Schistosoma mansoni* to *in vivo* and *in vitro* praziquantel treatment. *International Journal for Parasitology* **34**, 527–533.
- Pica-Mattoccia L, Doenhoff MJ, Valle C, Basso A, Troiani AR, Liberti P, Festucci A, Guidi A and Cioli D** (2009) Genetic analysis of decreased praziquantel sensitivity in a laboratory strain of *Schistosoma mansoni*. *Acta Tropica* **111**, 82–85.
- Pinto JG, Soares CP and Mittmann J** (2011) Assessment of *Leishmania major* and *Leishmania braziliensis* promastigote viability after photo-dynamic treatment with aluminum phthalocyanine tetrasulfonate (ALPcS<sub>4</sub>). *Journal of Venomous Animals and Toxins including Tropical Diseases* **17**, 300–307.
- Robichaux MA, Chenaux G, Ho HY, Soskis MJ, Dravis C, Kwan KY, Sestan N, Greenberg ME, Henkemeyer M and Cowan CW** (2014) EphB receptor forward signaling regulates area-specific reciprocal thalamic and cortical axon pathfinding. *Proceedings of the National Academy of Sciences of the USA* **111**, 2188–2193.
- Schwarz R, Kaspar A, Seelig J and Kunnecke B** (2002) Gastrointestinal transit times in mice and humans measured with 27Al and 19F nuclear magnetic resonance. *Magnetic Resonance in Medicine* **48**, 255–261.
- Serfilippi LM, Pallman DR and Russell B** (2003) Serum clinical chemistry and hematology reference values in outbred stocks of albino mice from three commonly used vendors and two inbred strains of albino mice. *Contemporary Topics in Laboratory Animal Science* **42**, 46–52.
- Smout MJ, Kotze AC, McCarthy JS and Loukas A** (2010) A novel high throughput assay for anthelmintic drug screening and resistance diagnosis by real-time monitoring of parasite motility. *PLoS Neglected Tropical Diseases* **4**, e885.
- Soskis MJ, Ho HY, Bloodgood BL, Robichaux MA, Malik AN, Ataman B, Rubin AA, Zieg J, Zhang C, Shokat KM, Sharma N, Cowan CW and Greenberg ME** (2012) A chemical genetic approach reveals distinct EphB signaling mechanisms during brain development. *Nature Neuroscience* **15**, 1645–1654.
- Tekwu EM, Anyan WK, Boamah D, Baffour-Awuah KO, Keyetat Tekwu S, Penlap Beng V, Nyarko AK and Bosompem KM** (2016) Mechanically produced schistosomula as a higher-throughput tools for phenotypic pre-screening in drug sensitivity assays: current research and future trends. *Biomarker Research* **4**, 21.
- Tran MH, Freitas TC, Cooper L, Gaze S, Gatton ML, Jones MK, Lovas E, Pearce EJ and Loukas A** (2010) Suppression of mRNAs encoding tegument tetraspanins from *Schistosoma mansoni* results in impaired tegument turnover. *PLoS Pathogens* **6**, e1000840.
- Xiao SH, Keiser J, Chen MG, Tanner M and Utzinger J** (2010) Research and development of antischistosomal drugs in the People's Republic of China a 60-year review. *Advances in Parasitology* **73**, 231–295.
- Xiao SH, Sun J and Chen MG** (2018) Pharmacological and immunological effects of praziquantel against *Schistosoma japonicum*: a scoping review of experimental studies. *Infectious Diseases of Poverty* **7**, 9.
- You H, Zhang W, Moertel L, McManus DP and Gobert GN** (2009) Transcriptional profiles of adult male and female *Schistosoma japonicum* in response to insulin reveal increased expression of genes involved in growth and development. *International Journal for Parasitology* **39**, 1551–1559.
- You H, Zhang W, Jones MK, Gobert GN, Mulvenna J, Rees G, Spanevello M, Blair D, Duke M, Brehm K and McManus DP** (2010) Cloning and characterisation of *Schistosoma japonicum* insulin receptors. *PLoS ONE* **5**, e9868.
- You H, McManus DP, Hu W, Smout MJ, Brindley PJ and Gobert GN** (2013) Transcriptional responses of *in vivo* praziquantel exposure in schistosomes identifies a functional role for calcium signalling pathway member CamKII. *PLoS Pathogens* **9**, e1003254.
- You H, McManus DP and Gobert GN** (2015) Current and prospective chemotherapy options for schistosomiasis. *Expert Opinion on Orphan Drugs* **3**, 195–205.
- Zhang W, Li J, Duke M, Jones MK, Kuang L, Zhang J, Blair D, Li Y and McManus DP** (2011) Inconsistent protective efficacy and marked polymorphism limits the value of *Schistosoma japonicum* tetraspanin-2 as a vaccine target. *PLoS Neglected Tropical Diseases* **5**, e1166.